AXIM Biotechnologies, Inc.

[Not Yet Scheduled]
AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research, development and production of cannabinoid-based pharmaceutical and nutraceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.

AXIM’s flagship pharmaceutical product, MedChew® with dronabinol, is planned to undergo a bioequivalence study in the near future to fast track through FDA as an alternative to approved Marinol. For more information, please visit www.AXIMBiotech.com.
Ticker:
AXIM
Exchange:
OTC
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
MedChew with dronabinol
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
AXIM Biotechnologies, Inc.